Osmetech Licenses Warfarin-Dosing SNP From Marshfield Clinic

Nov 02, 2007

NEW YORK (GenomeWeb News) - Osmetech said today it has exclusively licensed a molecular biomarker from Marshfield Clinic, a clinical and research facility in western Wisconsin, that it plans develop into a genetic test for determining appropriate warfarin doses.

Osmetech plans to develop, manufacture, and sell a genetic test based on the biomarker. Osmetech CEO James White said the biomarker will be used on the company’s XT-8 platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Silencing for Preeclampsia

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

Settlement Expected in Duke Case

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

This Week in PNAS

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

Something Different

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

Main menu